Biocept, Inc. (NASDAQ:BIOC) is set to announce its earnings results after the market closes on Thursday, August 10th.

Biocept, Inc. (BIOC) opened at 1.42 on Wednesday. The company’s market capitalization is $37.77 million. The company has a 50 day moving average of $1.39 and a 200 day moving average of $1.69. Biocept, Inc. has a 1-year low of $0.74 and a 1-year high of $3.39.

COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at

Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Biocept from a “buy” rating to a “hold” rating in a report on Tuesday, May 9th. ValuEngine upgraded Biocept from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Finally, Westpark Capital reiterated an “outperform” rating on shares of Biocept in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Biocept currently has an average rating of “Buy” and a consensus target price of $2.31.

About Biocept

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Earnings History for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with's FREE daily email newsletter.